Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Werewolf Therapeutics Inc (HOWL)

Werewolf Therapeutics Inc (HOWL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 70,855
  • Shares Outstanding, K 44,563
  • Annual Sales, $ 19,940 K
  • Annual Income, $ -37,370 K
  • EBIT $ -58 M
  • EBITDA $ -57 M
  • 60-Month Beta 0.30
  • Price/Sales 3.51
  • Price/Cash Flow N/A
  • Price/Book 0.77

Options Overview Details

View History
  • Implied Volatility 524.19% ( +319.06%)
  • Historical Volatility 69.37%
  • IV Percentile 98%
  • IV Rank 61.30%
  • IV High 845.37% on 10/16/24
  • IV Low 15.47% on 10/15/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 13
  • Volume Avg (30-Day) 65
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 3,493
  • Open Int (30-Day) 3,276

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.43
  • Number of Estimates 5
  • High Estimate -0.22
  • Low Estimate -0.80
  • Prior Year -0.33
  • Growth Rate Est. (year over year) -30.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3800 +15.22%
on 12/19/24
2.1400 -25.70%
on 11/25/24
-0.0500 (-3.05%)
since 11/20/24
3-Month
1.3800 +15.22%
on 12/19/24
4.1800 -61.96%
on 10/23/24
-0.6000 (-27.40%)
since 09/20/24
52-Week
1.3800 +15.22%
on 12/19/24
8.1939 -80.60%
on 02/26/24
-1.2900 (-44.79%)
since 12/20/23

Most Recent Stories

More News
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference

HOWL : 1.5900 (+1.27%)
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

HOWL : 1.5900 (+1.27%)
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

HOWL : 1.5900 (+1.27%)
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases

HOWL : 1.5900 (+1.27%)
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

HOWL : 1.5900 (+1.27%)
RSI Oversold: 2 Stocks (HOWL, WKHS) Potentially Signaling a Contrarian Buy

Sometimes equities that have been pushed too far down are at risk of surprisingly bouncing back.

HOWL : 1.5900 (+1.27%)
WKHS : 0.8034 (+6.20%)
Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights

- FDA granted IND clearance for lead candidate WTX-124 for evaluation as a treatment for advanced solid tumors - - Submission of IND application for...

HOWL : 1.5900 (+1.27%)
Werewolf Therapeutics to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative...

HOWL : 1.5900 (+1.27%)
Werewolf Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights

- Entered exclusive global license and collaboration agreement with Jazz Pharmaceuticals to develop and commercialize WTX-613; received $15.0M upfront...

HOWL : 1.5900 (+1.27%)
Werewolf Therapeutics Presents Promising Preclinical Data on its Two Lead INDUKINE™ Molecules at AACR 2022 Annual Meeting

WTX-124 demonstrated high tumor selectivity and generated significant anti-tumor activity in a CD8+ T cell-dependent manner WTX-330 surrogate demonstrated...

HOWL : 1.5900 (+1.27%)

Business Summary

Werewolf Therapeutics Inc. is a biopharmaceutical company. It involved in the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer. Werewolf Therapeutics Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 1.7900
2nd Resistance Point 1.7100
1st Resistance Point 1.6500
Last Price 1.5900
1st Support Level 1.5100
2nd Support Level 1.4300
3rd Support Level 1.3700

See More

52-Week High 8.1939
Fibonacci 61.8% 5.5910
Fibonacci 50% 4.7870
Fibonacci 38.2% 3.9829
Last Price 1.5900
52-Week Low 1.3800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar